Downloads
Abstract
Background: Addressing the increasing antibiotic resistance, including clarithromycin, levofloxacin resistance, which affects Helicobacter pylori eradication therapy, is a challenge for clinicians in Vietnam nowadays. The objective of this study was to determine the efficacy of bismuth added to triple therapy (RAM-B) as a first - line treatment regimen for Helicobacter pylori infection and its side effects in a Central region, Vietnam.
Methods: A prospective study was undertaken from May 2018 to September 2019. A total of 46 patients with Helicobacter pylori infection were enrolled and received Helicobacter pylori eradication therapy with bismuth added to triple therapy (rabeprazole, amoxicillin, metronidazole) for 14 days (RAM-B).
Results: A total of 46 patients completed triple therapy with bismuth added for Helicobacter pylori eradication. The eradication rates in the intention to treat were 87.0%. Rates of adverse events were 34.8% and allmost was mild.
Conclusion: Bismuth added to standard therapy could be acceptable as a firstline treatment regimen for Helicobacter pylori eradication in patients. In particular, in areas with high resistant or multiple antibiotic resistant Helicobacter pylori, it is advisable to consider bismuth add - on therapy as the first - line treatment regimen.
References
Phan TN, Santona A, Tran TNH, Cappuccinelli P, Rubino S, Paglietti B. Genotyping of Helicobacter pylori shows high diversity of strains circulating in central Vietnam. Infection, Genetics and Evolution. 2017;52:19-25.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Official journal of the American College of Gastroenterology| ACG. 2017;112:212-239.
Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69. e14.
Malfertheiner P, Megraud F, O’morain C, Gisbert J, Kuipers E, Axon A, et al. Management of Helicobacter pylori infection the Maastricht V/Florence consensus report. Gut. 2017;66:6-30.
Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870-878.
Graham DY, Lee S-Y. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterology Clinics. 2015;44:537-563.
Choe JW, Jung SW, Kim SY, Hyun JJ, Jung YK, Koo JS, et al. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton ‐ pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter. 2018;23:e12466.
Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta ‐ analysis. Helicobacter. 2019;24:e12565.
Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first - line Helicobacter pylori therapy. Gut. 2015;64:1715-1720.
Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, et al. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. Journal of clinical gastroenterology. 2013;47:233.
Ha TMT, Le PTQ, Nguyen VN, Phan TN, Paglietti B. Helicobacter pylori 23S rRNA gene mutations associated with clarithromycin resistance in chronic gastritis in Vietnam. The Journal of Infection in Developing Countries. 2018;12:526-532.
Phan TN, Santona A, Tran TNH, Cappuccinelli P, Rubino S, Paglietti B. High rate of levofloxacin resistance in a background of clarithromycin - and metronidazole - resistant Helicobacter pylori in Vietnam. International journal of antimicrobial agents. 2015;45:244-248.
Phan TN, Tran TNH, Santona A, Rubino S, Paglietti B. Antimicrobial resistance in Helicobacter pylori: current situation and management strategy in Vietnam. The Journal of Infection in Developing Countries. 2015;9:609-613.
Tran VH, Ha TMT, Le PTQ, Phan TN, Tran TNH. Characterisation of point mutations in domain V of the 23S rRNA gene of clinical Helicobacter pylori strains and clarithromycin - resistant phenotype in central Vietnam. J Glob Antimicrob Resist. 2019;16:87-91.
Cường TĐ, Huy TV. Đánh giá hiệu quả của phác đồ RBMT ở bệnh nhân viêm dạ dày mạn nhiễm Helicobacter Pylori đã thất bại với phác đồ ba thuốc. Tạp chí Nội khoa. 2017;4-2017.
Huệ ĐNQ, Huy TV, Hải NT. Viêm dạ dày mạn do Helicobacter pylori: hiệu quả tiệt trừ của phác đồ bốn thuốc có bismuth (EBMT). Tạp chí Y Dược học. 2016; tập 6(2) - Số 32/2016; Tr. 148-157.
Huy TV, Triều NTM. Nghiên cứu hiệu quả điều trị của phác đồ Rabeprazole - BismuthTetracyclin - Metronidazole ở bệnh nhân viêm dạ dày mạn có Helicobacter pylori dương tính. Tạp chí Y Dược học. 2016; tập 6, số 3, 2016, tr. 31-35.
Tường TTK. Hiệu quả điều trị của phác đồ 4 thuốc có bismuth trong điều trị nhiễm Helicobacter pylori Tạp chí Y Dược Học. 2017; tập 7, số 3, tr. 29-34.
| Published | 29-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 80 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.80.18 | |
| Keywords | Helicobacter pylori, phác đồ 3 thuốc bổ sung bismuth, RAM-B Helicobacter pylori eradication, triple therapy plus bismuth, bismuth supplements |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Journal of Clinical Medicine Hue Central Hospital